CUE vs MTB · rev $9.3M vs P/E 12, $30.99B cap
Cue Biopharma (CUE) versus M&T Bank Corporation (MTB) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
M&T Bank Corporation (MTB) is a banks - regional company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
MTB does not have a complete income-statement cache yet.
CUE currently screens at market cap $59.5M. MTB currently screens at market cap $30.99B and trailing P/E 11.9.
Not investment advice. Open the CUE and MTB stock pages for the full models.
Not investment advice.